Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Show other versions (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Format:	Journal article
Sprog:	English
Udgivet:	2008

Lignende værker

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
af: Clerico, M, et al.
Udgivet: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
af: Clerico, M, et al.
Udgivet: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
af: Clerico, M, et al.
Udgivet: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
af: Clerico, M, et al.
Udgivet: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
af: Clerico, M, et al.
Udgivet: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
af: Valéria Coelho Santa Rita Pereira, et al.
Udgivet: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
af: Clerico, M, et al.
Udgivet: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
af: Clerico, M, et al.
Udgivet: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
af: GJ Melendez-Torres, et al.
Udgivet: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
af: E.J. Ramos González, et al.
Udgivet: (2021-05-01)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
af: Andrew F Tyler, et al.
Udgivet: (2013-01-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
af: Clerico, M, et al.
Udgivet: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
af: Clerico, M, et al.
Udgivet: (2006)

Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
af: Joanna Roskal-Wałek, et al.
Udgivet: (2021-09-01)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
af: N. Y. Lasch
Udgivet: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
af: Katarzyna Kapica-Topczewska, et al.
Udgivet: (2019-01-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
af: G. J. Melendez-Torres, et al.
Udgivet: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
af: G. Ya. Shvarts
Udgivet: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
af: Özlem Taşkapılıoğlu, et al.
Udgivet: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
af: Özlem Taşkapılıoğlu, et al.
Udgivet: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
af: Oscar Fernández
Udgivet: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
af: Massimiliano Mirabella, et al.
Udgivet: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
af: Mikhail Melnikov, et al.
Udgivet: (2020-01-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
af: Oscar Fernández
Udgivet: (2012-04-01)

Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.
af: Niklas Bergvall, et al.
Udgivet: (2014-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
af: Methma Udawatta, et al.
Udgivet: (2024-04-01)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis
af: Attila Onmez, et al.
Udgivet: (2013-12-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
af: Aaron Boster, et al.
Udgivet: (2011-09-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
af: C. Halasan, et al.
Udgivet: (2020-01-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
af: P Tappenden, et al.
Udgivet: (2004-06-01)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
af: Caporro M, et al.
Udgivet: (2014-08-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
af: Anna Gil-Sánchez, et al.
Udgivet: (2024-04-01)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
af: Anne Waschbisch, et al.
Udgivet: (2011-01-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
af: Genaro Gabriel Ortíz, et al.
Udgivet: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
af: Arielle Kasindi, et al.
Udgivet: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
af: Arthur Komlosh, et al.
Udgivet: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
af: Ioana S. Barac, et al.
Udgivet: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
af: T. E. Shmidt
Udgivet: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
af: Ignacio Casanova, et al.
Udgivet: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
af: Justin M. Honce, et al.
Udgivet: (2020-09-01)